Each material 8-K filed by an S&P 1500 company, read and summarized: what happened, the key numbers, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). This page lists the last 45 days; every brief stays on its company's 8-K page (1506 companies, A–Z).
Solaris Energy Infrastructure's subsidiary agreed on October 29, 2026 to provide about 900 megawatts of power generation, balance of plant equipment and operations and maintenance services to an existing investment-grade industrial and technology customer. The agreement has an initial 15-year term per deployment, with an option to extend for another 15 years, and deployments are expected to begin in the first half of 2027 and scale through 2028.
Capacity covered: approximately 900 megawatts of power generation
Initial term: 15 years for each deployment, with an option to extend 15 more years
Timing: deployments expected to begin in the first half of 2027 and scale through 2028
Customer: a leading, investment-grade, diversified industrial and technology company that is already a Company customer
Roivant and its subsidiary Priovant reported that brepocitinib 45 mg met the primary endpoint and all key secondary endpoints in the two identical Phase 3 CLARITY-1 and CLARITY-2 trials in non-infectious uveitis, with 371 patients enrolled. Priovant plans to file a supplemental New Drug Application for NIU in the first half of calendar 2027, which would be the next step toward a possible new treatment for the condition. The filing furnishes the press release under Regulation FD and contains no financial results.
Primary endpoint (time to treatment failure) met in CLARITY-1 (N=166) and CLARITY-2 (N=204); 371 patients enrolled in total
Median time to treatment failure was greater than 48 weeks in both studies, versus about 12 weeks on placebo (p<0.0001 in both)
Pooled, 62% of brepocitinib patients achieved steroid-free quiescence at Week 48, versus 20% on placebo
Priovant intends to file the sNDA in the first half of calendar 2027; Roivant investor call set for 8:00 a.m. ET on October 21, 2026
3M entered into an expanded strategic commercial relationship with a subsidiary of Amazon.com, Inc. and issued that subsidiary a seven-year warrant to buy up to 3,162,015 shares of 3M common stock at $164.89 per share. The filing says 85% of the warrant shares vest based on Amazon payments for optical connectivity and other Data Center products, with full vesting once cumulative payments reach $6 billion. For shareholders, the warrant adds potential dilution, though its vesting ties it to future purchases.
Warrant covers up to 3,162,015 shares of 3M common stock over seven years
Exercise price is $164.89 per common share
85% of warrant shares vest with Amazon payments for optical connectivity and other Data Center products; full vesting at $6 billion in cumulative payments
Remaining warrant shares vest subject to event-based milestones not specified in the filing
Regeneron and Sanofi amended their antibody collaboration on October 1, 2026, to co-develop and co-commercialize four new long-acting antibodies. Sanofi will pay Regeneron a $1.0 billion upfront payment, with up to $7.0 billion more in milestones, and the two companies will share global profits equally. Regeneron also expects a third-quarter 2026 acquired IPR&D charge of about $22 million, or $0.18 per diluted share, and agreed to dismiss a lawsuit against Sanofi.
Sanofi will pay Regeneron a $1.0 billion upfront payment under the Sixth Amendment dated October 1, 2026.
Regeneron is eligible for up to an additional $7.0 billion in development, regulatory, and commercial milestone payments.
Regeneron expects a third-quarter 2026 acquired IPR&D charge of about $22 million pre-tax, reducing GAAP and non-GAAP EPS by about $0.18 per diluted share.
Regeneron agreed to dismiss its lawsuit over Sanofi's obligations to provide information on Dupixent commercialization and audit rights.
Atlas Energy Solutions disclosed two equipment purchase agreements, signed September 18, 2026, by indirect subsidiaries with Wyoming Machinery Company d/b/a Energy Solutions, totaling roughly $613.5 million for a specific power generation project. The filing does not report revenue, earnings or guidance, so it gives shareholders a clearer view of capital commitments but no direct measure of financial performance.
Balance-of-plant equipment purchase agreement for approximately $340.5 million, with deliveries between June 2027 and December 2027 and 10% of the price withheld until WMC completes its obligations.
Generator purchase agreement for approximately 328 megawatts of equipment and services at approximately $273.0 million, with payments from September 2026 through January 2028 and tariffs passed through at actual amounts charged by Caterpill
The balance-of-plant agreement can be terminated for convenience on at least 14 days' written notice, with Shackelford paying amounts then due plus WMC's documented costs and related charges.
The power project is supported by a cost reimbursement agreement with a leading frontier AI lab, which the filing identifies as the intended off taker.
Akamai entered two project plans under its existing Anthropic master services agreement, under which Anthropic has committed to pay about $11.6 billion over initial seven-year terms, subject to termination rights and delivery requirements. Akamai also issued Anthropic a warrant for Series B preferred stock that would convert into up to about 7.7 million common shares, roughly 5% of shares outstanding, with about 2% expected to vest on the initial commitment. Akamai said the deal is not expected to affect its 2026 revenue guidance but will raise 2026 capital expenditures by about $1.7 billion, and the filing's total capital expenditure estimate for the commitment is about $5.5 billion.
Anthropic has committed to pay about $11.6 billion in aggregate under Project Plans 2 and 3, each with an initial seven-year term, dated September 18, 2026
Warrant for 387,051 shares of Series B Non-Voting Convertible Preferred Stock, each convertible into 20 common shares, for up to 7,741,020 common shares on an as-converted basis
Total capital expenditures tied to the $11.6 billion commitment are estimated at about $5.5 billion, with about $1.7 billion more in 2026 capital expenditures for supply chain components including memory
Akamai anticipates no impact to its 2026 revenue guidance
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Frequently asked questions
Which filings get a brief?
Form 8-K filings by S&P 500, MidCap 400 and SmallCap 600 companies that report a material event: results (Item 2.02), deals (1.01, 2.01), executive changes (5.02), restructuring (2.05), impairments (2.06), delisting notices (3.01), restatements (4.02), cybersecurity incidents (1.05), bankruptcy (1.03) and Regulation FD or other events (7.01, 8.01). Routine filings such as vote results or exhibits only are skipped.
How is the impact score set?
The model rates each filing from 1 (routine) to 5 (major, such as a merger, bankruptcy or restatement) based only on what the filing says. It is a reading aid for sorting the day's filings, not a prediction of how the stock will move.
How quickly do briefs appear?
The SEC filing feed is checked every hour on weekdays between 7 am and 9 pm Eastern; briefs follow within that hour or, when many filings arrive at once, after a batch completes later the same day.
Are older briefs kept?
Yes. This page shows the last 45 days, but every brief ever published stays online: each has its own page, and each company has an 8-K page listing all of its briefs, newest first, linked from its stock page and from the A-Z list of companies.